Large-scale testing (Phase 3)UnknownNCT06140186What this trial is testingEfficacy and Safety of Timolol for TKI Induced ParonychiaWho this might be right forParonychia Queen Mary Hospital, Hong Kong 40
Early research (Phase 1)Study completedNCT02451553What this trial is testingAfatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary CancerWho this might be right forAdvanced Malignant Solid NeoplasmBile Duct CarcinomaRecurrent Malignant Solid Neoplasm+4 more University of Washington 41
Large-scale testing (Phase 3)Study completedNCT02864251What this trial is testingNivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyWho this might be right forNon-Small-Cell Lung Carcinoma Bristol-Myers Squibb 367
Very early researchStudy completedNCT00863122What this trial is testingConcentration and Activity of Lapatinib in Vestibular SchwannomasWho this might be right forVestibular SchwannomaNF2Neurofibromatosis 2+2 more Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 26
Testing effectiveness (Phase 2)Study completedNCT00045487What this trial is testingErlotinib in Treating Patients With Advanced Kidney CancerWho this might be right forKidney Cancer The University of Texas Health Science Center at San Antonio 41
Not applicableUnknownNCT00815971What this trial is testingMutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With ErlotinibWho this might be right forNon-Small Cell Lung Cancer Aarhus University Hospital 300
Testing effectiveness (Phase 2)Ended earlyNCT05636267What this trial is testingStudy of AK119 and AK112 With or Without Chemotherapy for NSCLC PatientsWho this might be right forNSCLC Akeso 59
Testing effectiveness (Phase 2)Study completedNCT02616393What this trial is testingPhase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal MetastasesWho this might be right forNon-Small Cell Lung CancerLeptomeningeal MetastasesBrain Metastases Kadmon Corporation, LLC 36
Testing effectiveness (Phase 2)Study completedNCT04147351What this trial is testingA Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.Who this might be right forNSCLC Stage IIIB~IV National Taiwan University Hospital 22
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479What this trial is testingSacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain MetastasesWho this might be right forNSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis Zhejiang Cancer Hospital 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122717What this trial is testingOsimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerWho this might be right forNon-Small Cell Lung Cancer Dana-Farber Cancer Institute 48
Not applicableUnknownNCT05136014What this trial is testingEvaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid ModelWho this might be right forLung CancerLung AdenocarcinomaEGFR Activating Mutation+2 more Central Hospital, Nancy, France 200
Testing effectiveness (Phase 2)Ended earlyNCT03222622What this trial is testingStudy of Icotinib Hydrochloride Cream in Patients With Mild to Moderate PsoriasisWho this might be right forMild to Moderate Psoriasis Betta Pharmaceuticals Co., Ltd. 136
Very early researchNot Yet RecruitingNCT07498595What this trial is testingTILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLCWho this might be right forEGFR-TKI-resistant Non-Small Cell Lung Cancer Tianjin Medical University General Hospital 50
Early research (Phase 1)Study completedNCT00083057What this trial is testingGefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckWho this might be right forHead and Neck Cancer National Institutes of Health Clinical Center (CC) 30
Early research (Phase 1)Active Not RecruitingNCT05364073What this trial is testingStudy of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsWho this might be right forNon-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more ArriVent BioPharma, Inc. 160
Not applicableStudy completedNCT03059641What this trial is testingTherapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in ChinaWho this might be right forLung NeoplasmsLung Cancer, Nonsmall CellAdenocarcinoma of Lung+1 more Geneplus-Beijing Co. Ltd. 300
Early research (Phase 1)Ended earlyNCT02206763What this trial is testingErlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)Who this might be right forEGFR Mutated EGFR TKI Naive Metastatic NSCLC Sierra Oncology LLC - a GSK company 11
Testing effectiveness (Phase 2)Looking for participantsNCT02491099What this trial is testingA Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous CarcinomaWho this might be right forHER2/Neu+ Uterine Serous Carcinoma Yale University 50
Testing effectiveness (Phase 2)Looking for participantsNCT05456256What this trial is testingLP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaWho this might be right forAdenocarcinoma of LungCarcinoma, Non-Small-Cell Lung Lantern Pharma Inc. 90